RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer

BACKGROUND: Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with limited systemic treatment options. RX-5902 is a novel anti-cancer agent that inhibits phosphorylated-p68 and thus attenuates nuclear β-catenin signaling. The purpose of this study was to evaluate the abilit...

Descripción completa

Detalles Bibliográficos
Autores principales: Tentler, John J., Lang, Julie, Capasso, Anna, Kim, Deog Joong, Benaim, Ely, Lee, Young B., Eisen, Andrew, Bagby, Stacey M., Hartman, Sarah J., Yacob, Betelehem W., Gittleman, Brian, Pitts, Todd M., Pelanda, Roberta, Eckhardt, S. Gail, Diamond, Jennifer R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7641792/
https://www.ncbi.nlm.nih.gov/pubmed/33148223
http://dx.doi.org/10.1186/s12885-020-07500-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7641792/
https://www.ncbi.nlm.nih.gov/pubmed/33148223
http://dx.doi.org/10.1186/s12885-020-07500-1

Ejemplares similares